BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Top 20 Compelling Business Books for Progress - 2Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- 3Study reveals links between global food systems, obesity, and climate change
- 4Cyber Monday 2025 streaming deal: Get $42 off six months of Apple TV
- 5A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- Ten Awesome Authentic Realities That Will Leave You Interested
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- African nations push to recognize crimes of colonialism in Algeria
- Trump signs bill allowing whole milk to return to school lunches
- 8 Espresso Bean Starting points All over the Planet
- Share your pick for the tree that you love for its novel magnificence!
- James Webb Space Telescope finds strongest evidence yet for atmosphere around rocky exoplanet: 'It's really like a wet lava ball'
- Vote In favor of Your Favored Treat
- Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
